Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as a delayed‑release tablet for oral use. It is indicated for the prevention of organ rejection in kidney transplantation and other solid organ transplants, and is marketed in the European Union under strict quality standards.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The product conforms to EU GMP requirements and is distributed under controlled conditions to ensure product integrity.

Myfortic (mycophenolic acid) is an antimetabolite immunosuppressant used in solid organ transplantation.

- Kidney transplantation: helps prevent graft rejection and maintains kidney function. - Liver transplantation: reduces the risk of acute and chronic rejection of the transplanted liver. - Heart and lung transplantation: supports long‑term graft survival by suppressing immune response.

Myfortic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient head pain. - Upper respiratory infections: increased susceptibility.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Severe infections: opportunistic or systemic infections. - Hepatotoxicity: elevated liver enzymes or liver injury. - Progressive multifocal leukoencephalopathy: rare viral brain infection. - Malignancy risk: increased incidence of certain cancers with long‑term use.

Before initiating Myfortic, clinicians should consider several safety measures.

- Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess liver function: periodic LFTs to identify hepatotoxicity. - Avoid live vaccines: increased risk of infection in immunosuppressed patients. - Use caution in renal impairment: dose adjustment may be required. - Review concomitant immunosuppressants: assess cumulative infection risk. - Store below 25°C: keep in the original pack, protect from moisture.

Myfortic can interact with various medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: markedly reduce mycophenolic acid exposure. - Live vaccines: may cause severe infection due to immunosuppression. - Concurrent potent immunosuppressants (e.g., high‑dose steroids): increase risk of serious infections.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption of the delayed‑release tablet. - Azathioprine: additive myelosuppression requiring blood count monitoring. - NSAIDs: heightened risk of gastrointestinal irritation. - Cholestyramine or colestipol: may bind drug and lower systemic levels.